We are located in the Toscana Life Sciences (TLS) incubator in the GlaxoSmithKline research center, which provides space for nurturing startups in the life sciences.

This location provides access to costly infrastructure and technology that would otherwise be out of reach for startups, enabling us to effectively meet stringent pharmaceutical standards.

Materia Medica Processing (MMP) is at the forefront of the medical cannabis sector in Italy and is now poised to expand significantly, capitalizing on recent regulatory advancements. The company has obtained a pharmaceutical license in May 2024, becoming a major player in the Italian medical market, predominantly comprised of cannabis flower.

With the United States rescheduling cannabis and Germany’s new Cannabis Act as of April 1, 2024, GMP certification ensures we meet the highest standards for manufacturing and be ready for future  growth driven by similar policies potentially being adopted across Europe.